Comparison of the Analgesic Efficacy of Adductor Canal Block and Combined Adductor Canal Block Plus IPACK Block in Knee Surgery
Condition(s) studied
Investigational drug(s) / intervention(s)
Adductor Canal Block Group (Group I): All patients in Group I will receive a preoperative adductor canal block. In all groups, an intravenous patient-controlled analgesia device containing morphine will be administered for postoperative pain management.
Adductor Canal + iPACK Block Group (Group II)": All patients in Group II will receive a preoperative adductor canal block combined with an iPACK block. Postoperatively, all patients in both groups will be provided with intravenous patient-controlled analgesia containing morphine for pain management.
Study summary
To evaluate the effectiveness of Adductor Canal Block and combined Adductor Canal plus IPACK block in reducing postoperative pain and analgesic requirements in patients undergoing knee surgery.
Eligibility
Primary outcome measure(s)
- opioid consumption — 24 hours after surgery
In the recovery room, all patients will given a patient- controlled analgesia device containing morphine 0.5 mg/ml, set to deliver a 1mg bolus dose of morphine with an 15 min lockout time and 4 mg 1 h limit.Total morphine consumption during the 24 hours postoperative period will recorded at 5 times intervals ( 2, 4, 6, 12, 24 hours). - Verbal analog Pain Scores on rest and movement — 24 hours after surgery
A Research assistant, blinded to the group allocation, interviewed patients and collected data at 5 times intervals ( 2, 4, 6, 12, 24, hours) in the 24 hours postoperatively. Patients were asked to rate their pain using verbal analog scale, where 0= no pain and 10= worst pain possible.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Sibel Pehlivan | Kayseri | Talas | Recruiting |
| Sibel Seckin Pehlivan | Kayseri | Turkey (Türkiye) | Recruiting |
More TC Erciyes University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07526831 on ClinicalTrials.gov ↗ ← All trials in Turkey